

Appl. No. : 09/913,909
Filed : 17 August 2001

AMENDMENTS TO THE CLAIMS

Please cancel Claims 1, 2, 7, 8, 14-22, and 24, and amend Claims 3, 5, 6, 9, 23, 25, and 26, all without prejudice, in order to cancel or excise non-elected subject matter.

1. (Canceled)
2. (Canceled)
- ² ~~3~~. (Currently amended) The pharmaceutical composition of Claim ¹ ~~6~~ 4, wherein the control sequence is a promoter.
- ³ ~~4~~. (Original) The pharmaceutical composition of Claim ² ~~3~~, wherein the promoter is the CMV immediate-early region 1 promoter.
- ⁴ ~~5~~. (Currently amended) The pharmaceutical composition of Claim ¹ ~~6~~ 4, further comprising an adjuvant.
- ¹ ~~6~~. (Currently amended) A pharmaceutical composition comprising a nucleic acid molecule encoding an Ebola virus structural gene product operatively-linked to a control sequence, in a pharmaceutically acceptable carrier, The pharmaceutical composition of Claim 2, wherein the Ebola virus structural gene product is the transmembrane form of the Ebola virus glycoprotein.
7. (Canceled)
8. (Canceled)
- ⁵ ~~9~~. (Currently amended) A method of producing a vaccine against disease caused by infection by Ebola virus, comprising the steps of:
 - a) administering the pharmaceutical composition of Claim ¹ ~~6~~ 4 to a test host to determine an amount and a frequency of administration thereof to elicit a protective immune response in said host; and
 - b) formulating said pharmaceutical composition in a form suitable for administration to a treatable host in accordance with said determined amount and frequency of administration.
- ⁶ ~~10~~. (Original) A vaccine comprising a nucleic acid molecule encoding the transmembrane form of the Ebola virus glycoprotein operatively-linked to a control sequence, in a pharmaceutically acceptable carrier.
- ⁶ ~~11~~. (Original) The vaccine of Claim ⁶ ~~10~~, wherein the control sequence is a promoter.

Appl. No. : 09/913,909
Filed : 17 August 2001

¹² ~~12.~~ (Original) The vaccine of Claim 11, wherein the promoter is the CMV immediate-early region 1 promoter.

⁷ ~~13.~~ (Original) The vaccine of Claim ⁶ ~~10~~, further comprising an adjuvant.

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Canceled)

⁸ ~~23.~~ (Currently amended) A method of immunizing a subject against hemorrhagic fever comprising the step of administering to the host an immunoeffective amount of the vaccine of any of Claims ⁶ ~~10~~ to ⁷ ~~13~~, The method of Claim 22, wherein the hemorrhagic fever is caused by infection with Ebola virus.

24. (Canceled)

⁹ ~~25.~~ (Currently amended) The method of Claim ⁸ ~~23~~ 22, wherein the host is a human and administration is by intramuscular injection.

¹⁰ ~~26.~~ (Currently amended) The method of Claim ⁸ ~~23~~ 22, wherein the subject receives a second administration of an immunoeffective amount of a vaccine against disease caused by infection by Ebola virus or Marburg virus.